CIPLA.BO - Cipla Limited

BSE - BSE Real Time Price. Currency in INR
646.00
+23.55 (+3.78%)
At close: 3:54PM IST
Stock chart is not supported by your current browser
Previous close622.45
Open622.55
Bid0.00 x 0
Ask0.00 x 0
Day's range619.35 - 647.50
52-week range508.10 - 678.00
Volume112,888
Avg. volume178,096
Market cap520.553B
Beta (3Y Monthly)0.18
PE ratio (TTM)35.85
EPS (TTM)18.02
Earnings date5 Nov 2018
Forward dividend & yield3.00 (0.47%)
Ex-dividend date2018-08-13
1y target estN/A
  • Reuters28 days ago

    Ugandan unit of Indian drugs firm Cipla raises $43.8 million in IPO: Renaissance Capital

    The Ugandan unit of India's pharmaceutical giant Cipla raised 167 billion Ugandan shillings ($43.8 million) from its oversubscribed initial public offering (IPO), an investment bank that helped advise on the transaction said on Monday. Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 percent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings and closed the first day of trading up 2.1 percent at 262 Ugandan shillings.

  • What Kind Of Shareholders Own Cipla Limited (NSE:CIPLA)?
    Simply Wall St.2 months ago

    What Kind Of Shareholders Own Cipla Limited (NSE:CIPLA)?

    A look at the shareholders of Cipla Limited (NSE:CIPLA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • Drugmaker Cipla's Ugandan unit prices IPO
    Reuters2 months ago

    Drugmaker Cipla's Ugandan unit prices IPO

    The Ugandan unit of Indian drugmaker Cipla priced its initial public offering on Tuesday at 256.5 shillings per share, aiming to raise $45 million from its listing on the Kampala stock exchange next month. Cipla Quality Chemical Industries, which is majority owned by India's third-largest drugmaker, is selling 657,179,319 shares, or an 18 percent stake in the company. Chief Executive Officer Emmanuel Katongole, in a statement, said the IPO would enable Ugandan investors to share in the company's success.

  • IANS2 months ago

    Cipla's Q1 consolidated net profit up 5%

    Mumbai, Aug 8 (IANS) Pharma major Cipla on Wednesday reported an increase of 4.86 per cent in its consolidated net profit during the first quarter (Q1) of 2018-19. According to the company, net profit ...

  • Reuters2 months ago

    Cipla first-quarter profit trumps estimates on strong domestic growth

    Indian drugmaker Cipla Ltd posted quarterly profit well above analysts' expectations, helped by strong growth in the domestic market. Net profit rose 10.4 percent from a year earlier to 4.51 billion rupees ...

  • Reuters2 months ago

    Uganda's Cipla Quality Chemical Industries says plans IPO, listing

    Ugandan drugmaker Cipla Quality Chemical Industries Ltd said on Thursday it plans an initial public offering and a listing on the East African country's stock exchange. The company said each of its shareholders would be "selling a minority of their stakes" in the IPO and that the transaction and potential listing had received regulatory approvals. The drug maker, majority-owned by India's pharmaceutical giant Cipla, was established in 2005 and has a manufacturing plant in the Ugandan capital Kampala.

  • What Should Investors Know About Cipla Limited’s (NSE:CIPLA) Future?
    Simply Wall St.4 months ago

    What Should Investors Know About Cipla Limited’s (NSE:CIPLA) Future?

    Cipla Limited’s (NSE:CIPLA) announced its latest earnings update in March 2018, which indicated that the company gained from a robust tailwind, leading to a double-digit earnings growth of 40.16%. InvestorsRead More...

  • Cipla gets USFDA nod for generic Testosterone Cypionate injection
    Moneycontrol4 months ago

    Cipla gets USFDA nod for generic Testosterone Cypionate injection

    The company has received final approval for its abbreviated new drug application (ANDA) for Testosterone Cypionate injection in the strengths of 100mg/ml and 200mg/ml from the US Food and Drug Administration (USFDA), Cipla said in a filing to BSE.

  • Cipla gets United States Food and Drug Administration nod for generic HIV drug
    Moneycontrol4 months ago

    Cipla gets United States Food and Drug Administration nod for generic HIV drug

    The Mumbai-based firm has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength, Cipla said in a statement.

  • Cipla gets USFDA nod for generic Isuprel injection
    Moneycontrol4 months ago

    Cipla gets USFDA nod for generic Isuprel injection

    The company has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc's Isuprel injection, Cipla said in a statement.

  • Cipla gains 2% on USFDA approval for generic Isuprel
    Moneycontrol4 months ago

    Cipla gains 2% on USFDA approval for generic Isuprel

    The company has received final approval for its abbreviated new drug application (ANDA) for Isoproterenol hydrochloride injection USP, 0.2mg/mL, single - use sterile Ampoule from the United States Food and Drug Administration (USFDA).

  • Cipla Shifts Focus To India To Drive Growth
    Bloomberg Quint4 months ago

    Cipla Shifts Focus To India To Drive Growth

    Cipla is looking at a billion dollar consolidated revenue for the domestic market in FY19.

  • Cipla partners with Eli Lilly to market diabetes drug Basaglar in India
    Moneycontrol4 months ago

    Cipla partners with Eli Lilly to market diabetes drug Basaglar in India

    Cipla expects to start commercialising Basaglar in India by end of this year.

  • Cipla rises nearly 3% as company to market Eli Lilly's diabetes drug
    Moneycontrol4 months ago

    Cipla rises nearly 3% as company to market Eli Lilly's diabetes drug

    Under this agreement, Lilly’s BASAGLAR that is manufactured by Lilly will be marketed and distributed in India by Cipla.

  • Buy Cipla; target of Rs 600: JM Financial
    Moneycontrol5 months ago

    Buy Cipla; target of Rs 600: JM Financial

    JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 600 in its research report dated May 23, 2018.

  • Cipla posts fourth quarter profit, misses estimates
    Reuters5 months ago

    Cipla posts fourth quarter profit, misses estimates

    Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates. Net profit came in at 1.79 billion rupees for the quarter ended ...

  • Cipla Q4 profit at Rs 153 cr versus loss last year; misses estimates
    Moneycontrol5 months ago

    Cipla Q4 profit at Rs 153 cr versus loss last year; misses estimates

    The operating profit margin expanded 100 basis points to 15.1 percent in Q4 from 14.1 percent in Q4FY17.

  • Q4 preview: Cipla to be back in black on improved sales from India and South Africa
    Moneycontrol5 months ago

    Q4 preview: Cipla to be back in black on improved sales from India and South Africa

    Cipla is likely to report a net profit of Rs 356.7 crore in the fourth quarter of FY18, according to estimates of Reuters poll of analysts.

  • Stempeutics partners with Cipla for its stem cell drug
    Moneycontrol5 months ago

    Stempeutics partners with Cipla for its stem cell drug

    "Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla," the company said in a statement.

  • Cipla Signs Marketing, Distribution Deal With MannKind For Diabetes Inhaler Afrezza
    Bloomberg Quint5 months ago

    Cipla Signs Marketing, Distribution Deal With MannKind For Diabetes Inhaler Afrezza

    Cipla enters into an agreement with MannKind Corporation to market inhaled insulin, Afrezza for diabetes patients.

  • Cipla enters into exclusive pact with US-based MannKind to sell inhaled insulin in India
    Moneycontrol5 months ago

    Cipla enters into exclusive pact with US-based MannKind to sell inhaled insulin in India

    Under the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI), while MannKind will manufacture and supply the drug

  • Cipla receives final approval for Phenylephrine Hydrochloride Injection
    Moneycontrol5 months ago

    Cipla receives final approval for Phenylephrine Hydrochloride Injection

    Cipla has received final approval for its abbreviated new drug application (ANDA) for Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10mg/mL) Pharmacy Bulk Package, Phenylephrine Hydrochloride Injection USP, 10 mg/mL SingleDose Vial and Exemestane Tablets, 25mg from the United States Food and Drug Administration (USFDA).

  • Cipla may test Rs 650 on robust Q4FY18 results: Akash Jain
    Moneycontrol6 months ago

    Cipla may test Rs 650 on robust Q4FY18 results: Akash Jain

    "The company is fairly valued at current market price. However, if Q4FY18 results are robust then we can expect a target of Rs 650 by FY19 end," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.

  • USFDA conducts inspection at Cipla's Indore facility
    Moneycontrol6 months ago

    USFDA conducts inspection at Cipla's Indore facility

    "The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.

  • Cipla gains 5% after USFDA inspection with no data integrity or repeat observations
    Moneycontrol6 months ago

    Cipla gains 5% after USFDA inspection with no data integrity or repeat observations

    The US Food and Drug Administration has recently completed its inspection of Cipla's Indore facility.